RE:RE:RE:RE:RE:RE:China Daily Article I think that was a good post, but not great.
what you may be missing is no one plunks down $2B without a hard look at the data.. to see if it supports an FDA approval.
oXiris data is one thing, but PMX data is another. Sepsis is a hard nut to crack.
If they have had a look ( it is somewhat open label after all) , IMO it's more likely they await top line results, with one finger on the trigger.
BTW $2B USD is darn close to $7 /share* ... so I'll give you partial marks. But next time, bring it home in terms that all here can understand, and show your rough work for additional part marks.
MM
* 2B /400M X 1.40